Cargando…
Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab
Endometrial cancer (EC) accounts for 2% of all new cancers. Advanced forms have a poor prognosis with barely 17% 5-year survival. The last few years improved our knowledge of EC with a new molecular classification derived from The Cancer Genome Atlas (TCGA). They are now divided between POLE mutant,...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243542/ https://www.ncbi.nlm.nih.gov/pubmed/37288137 http://dx.doi.org/10.2147/OTT.S368050 |